1. Home
  2. ELTX vs FCO Comparison

ELTX vs FCO Comparison

Compare ELTX & FCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELTX
  • FCO
  • Stock Information
  • Founded
  • ELTX 2011
  • FCO 1991
  • Country
  • ELTX United States
  • FCO United Kingdom
  • Employees
  • ELTX N/A
  • FCO N/A
  • Industry
  • ELTX Biotechnology: Pharmaceutical Preparations
  • FCO Investment Managers
  • Sector
  • ELTX Health Care
  • FCO Finance
  • Exchange
  • ELTX Nasdaq
  • FCO Nasdaq
  • Market Cap
  • ELTX 121.7M
  • FCO 85.6M
  • IPO Year
  • ELTX N/A
  • FCO N/A
  • Fundamental
  • Price
  • ELTX $8.09
  • FCO $6.50
  • Analyst Decision
  • ELTX Strong Buy
  • FCO
  • Analyst Count
  • ELTX 2
  • FCO 0
  • Target Price
  • ELTX $9.50
  • FCO N/A
  • AVG Volume (30 Days)
  • ELTX 46.9K
  • FCO 100.1K
  • Earning Date
  • ELTX 08-12-2025
  • FCO 01-01-0001
  • Dividend Yield
  • ELTX N/A
  • FCO 14.96%
  • EPS Growth
  • ELTX N/A
  • FCO N/A
  • EPS
  • ELTX N/A
  • FCO 0.43
  • Revenue
  • ELTX N/A
  • FCO N/A
  • Revenue This Year
  • ELTX N/A
  • FCO N/A
  • Revenue Next Year
  • ELTX N/A
  • FCO N/A
  • P/E Ratio
  • ELTX N/A
  • FCO $12.30
  • Revenue Growth
  • ELTX N/A
  • FCO N/A
  • 52 Week Low
  • ELTX $3.70
  • FCO $4.73
  • 52 Week High
  • ELTX $9.99
  • FCO $6.63
  • Technical
  • Relative Strength Index (RSI)
  • ELTX 62.14
  • FCO 65.74
  • Support Level
  • ELTX $7.76
  • FCO $6.42
  • Resistance Level
  • ELTX $8.94
  • FCO $6.59
  • Average True Range (ATR)
  • ELTX 0.37
  • FCO 0.09
  • MACD
  • ELTX -0.03
  • FCO 0.01
  • Stochastic Oscillator
  • ELTX 51.09
  • FCO 79.07

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.

About FCO abrdn Global Income Fund Inc.

abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories, Developed Markets, Investment Grade Developing Markets and Sub-Investment Grade Developing Markets.

Share on Social Networks: